Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test. Antimicrobial resistance (AMR) is one of the biggest global health challenges today. The emergence of multi-drug resistant pathogens has […]
Clinical Development Press Release
hemotune AG initiates joint feasibility project on the HemoSystem with AstraZeneca
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for [...]
Continue reading
Clinical Development Innovation Press Release
At the forefront of research into prevention of scar tissue formation after a heart attack
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Clinical Development Innovation Press Release
Resistell’s first patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell’s first patients recruited for international clinical study [...]
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™, Their Novel ATRAUMATIC Cervical Stabilizer from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading
Diversity Hemex Team Innovation
Empowering our people, transforming our world in 2023
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading
Marija Plodinec, CEO of Artidis (Img: Technologiepark Basel) “Artidis is based on the oldest diagnostic test on earth: palpation,” says Marija Plodinec, CEO and co-founder of Artidis AG. “In a nutshell, we palpate tissue on a molecular level,“ she adds with a twinkle. That’s because instead of a physician’s hand, Artidis runs a fine, high-precision […]